Evidence map›Paper›PMID 32424320›Full record

ArticleNature communications2020

Cas9-AAV6-engineered human mesenchymal stromal cells improved cutaneous wound healing in diabetic mice.

Waracharee Srifa, Nina Kosaric, Alvaro Amorin, Othmane Jadi, Yujin Park, Sruthi Mantri, Joab Camarena, Geoffrey C Gurtner, Matthew Porteus

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 78 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Waracharee SrifaDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-6821-2451
Nina KosaricProgram in Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Alvaro AmorinDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-3500-5085
Othmane JadiDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-2675-1916
Yujin ParkDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Sruthi MantriDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Joab CamarenaDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA.ORCID http://orcid.org/0000-0002-3102-5820
Geoffrey C GurtnerDepartment of Surgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Matthew PorteusDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, 94305, USA. mporteus@stanford.edu.ORCID http://orcid.org/0000-0002-3850-4648
Stanford University · USStanford Medicine · US

Funding

Reversal of Progenitor Cell Deficits in DiabetesR01DK074095 · NIDDK · UNIVERSITY OF ARIZONA · PI GURTNER, GEOFFREY C · 2005 to 2025
$6.4M
NIDDK NIH HHS R01 DK074095
6 · The paper itself

Abstract

Human mesenchymal stromal cells (hMSCs) are a promising source for engineered cell-based therapies in which genetic engineering could enhance therapeutic efficacy and install novel cellular functions. Here, we describe an optimized Cas9-AAV6-based genome editing tool platform for site-specific mutagenesis and integration of up to more than 3 kilobases of exogenous DNA in the genome of hMSCs derived from the bone marrow, adipose tissue, and umbilical cord blood without altering their ex vivo characteristics. We generate safe harbor-integrated lines of engineered hMSCs and show that engineered luciferase-expressing hMSCs are transiently active in vivo in wound beds of db/db mice. Moreover, we generate PDGF-BB- and VEGFA-hypersecreting hMSC lines as short-term, local wound healing agents with superior therapeutic efficacy over wildtype hMSCs in the diabetic mouse model without replacing resident cells long-term. This study establishes a precise genetic engineering platform for genetic studies of hMSCs and development of engineered hMSC-based therapies.

Indexed as

Mesenchymal Stem Cell TransplantationWound HealingAnimalsCell ProliferationCell SurvivalCRISPR-Associated Protein 9Cross-Linking ReagentsDependovirusDiabetes Mellitus, ExperimentalGene EditingGreen Fluorescent ProteinsHumansHydrogelsKineticsMesenchymal Stem CellsMiceCRISPR-Associated Protein 9Cross-Linking ReagentsGreen Fluorescent ProteinsHydrogelsProto-Oncogene Proteins c-sisVascular Endothelial Growth Factor A

Identifiers

PMID32424320
PMCPMC7235221
OpenAlexW3024110066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.